NACET (N-Acetylcysteine Ethyl Ester)

The lipophilic ethyl ester of NAC — solves the main pharmacokinetic weakness of parent NAC by crossing the blood-brain barrier ~7-30× more efficiently and raising brain glutathione (vs. NAC, which mostly raises peripheral/liver GSH). Animal data is robust: brain GSH elevation, neuroprotection in glutamate excitotoxicity, MPTP, and Parkinson's models. But the human evidence base is essentially zero RCTs — only case reports and tiny open-label series. For Dylan: WATCH-LIST. Mechanistically perfect for the MMA brain-protection thesis, practically un-actionable until a reliable supplier with COA emerges and a credible human signal lands. Not a V4-replacement decision today; revisit if a reputable third-party-tested vendor surfaces or if the V4 NAC is failing biomarker checks.

NACET is N-acetyl-L-cysteine with the carboxylic acid (-COOH) esterified to an ethyl group (-COOC2H5). That single chemical change transforms the molecule's pharmacokinetic profile:

1. Lipophilicity. Parent NAC is hydrophilic — the free carboxylic acid is ionized at physiological pH, making the molecule polar and poorly able to cross lipid bilayers. Esterification masks the carboxyl group, dramatically increasing log P. NACET passes through cell membranes (and the blood-brain barrier) by passive diffusion at far higher rates than NAC. Reported BBB penetration enhancements vs. NAC range ~7-30× depending on assay.

2. Oral bioavailability. Plain NAC has ~6-10% systemic oral bioavailability — the rest is deacetylated in gut wall and first-pass-metabolized in liver. NACET, being lipophilic and resistant to first-pass deacetylation, has been reported in animal pharmacokinetic studies at >50% bioavailability.

3. Intracellular esterase cleavage — the prodrug step. Once NACET is inside cells (including neurons, glia, hepatocytes, immune cells), ubiquitous intracellular esterases cleave the ester bond, releasing free NAC + ethanol. The NAC then deacetylates to L-cysteine, which enters the standard GSH-synthesis pathway. The "ethanol" liberation is trivial in quantity — at a 600-1200 mg NACET dose, the molar equivalent of ethanol is <50 mg, far below any pharmacologic threshold.

4. Brain GSH elevation — the headline difference vs. NAC. Because NACET delivers cysteine intracellularly within the brain, it raises brain (cortical, striatal, hippocampal) glutathione in animal models. NAC, in contrast, raises mostly peripheral GSH (liver, plasma) with smaller and slower brain elevations because cysteine has to cross the BBB indirectly. This is the central pharmacologic claim of NACET.

5. Direct ROS scavenger. Like NAC, after the ester is cleaved the free thiol on cysteine donates electrons to neutralize hydroxyl radicals, peroxynitrite, hypochlorous acid. Per-mole scavenging is similar to NAC; the difference is where the scavenging occurs (brain interior vs. mostly periphery).

6. Glutamate / xCT modulation — same as NAC, more brain-located. Because the cysteine is now delivered intracellularly within glia, the cystine-glutamate antiporter (xCT, system Xc-) substrate pool is more directly raised in brain. Theoretically translates to stronger glutamate-modulating effect on cortical / striatal / nucleus accumbens circuits than NAC. Not directly demonstrated in human psychiatric trials (none exist).

7. Mitochondrial GSH. Mitochondrial GSH is uniquely difficult to replenish from the cytosolic pool — there's a dedicated transporter that's slow and saturable. NACET has been shown in cell models to raise mitochondrial GSH more efficiently than NAC. Relevant for the energetic / membrane-protection thesis around DHA + astaxanthin synergy.

The single-line summary: NACET is what NAC should be for the brain — same downstream chemistry, much better delivery to the compartment that matters most for combat-sport brain protection.